Hemostemix Inc. (CVE:HEM – Get Free Report) fell 6.5% on Monday . The company traded as low as C$0.29 and last traded at C$0.29. 264,753 shares traded hands during trading, a decline of 61% from the average session volume of 676,660 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The business has a fifty day simple moving average of C$0.11 and a 200 day simple moving average of C$0.08. The stock has a market capitalization of C$25.26 million, a price-to-earnings ratio of -14.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Quiet Period Expirations Explained
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Options Trading – Understanding Strike Price
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
